Company Profiles

driven by the PitchBook Platform

Adimab

Adimab
2007 FOUNDED
PRIVATE STATUS
51-200 EMPLOYEES
Series F LATEST DEAL TYPE
$13.8M LATEST DEAL AMOUNT
$42.6M TOTAL AMOUNT RAISED
Description

Producer of yeast-based therapeutic human antibodies designed to offer unprecedented quality and speed from target to therapeutic lead. The company's therapeutic human antibodies involves in the discovery, maturation and production of yeast-based immunoglobulin, enabling healthcare professionals to treat cancer as well as autoimmune and infectious diseases.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
7 Lucent Drive
Lebanon, NH 03766
United States

+1 (603) 643-7110
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Adimab’s full profile, request a free trial.

Adimab Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series F) 16-Apr-2012 $13.8M $42.6M 00000 Completed Profitable
5. Later Stage VC (Series E) 30-Jan-2010 000 000.00 00000 Completed Profitable
4. Later Stage VC (Series D) 01-Oct-2009 00.000 000.00 00000 Completed Profitable
3. Later Stage VC (Series C) 20-Nov-2008 00.000 000.00 00000 Completed Startup
2. Early Stage VC (Series B) 25-Mar-2008 $3.18M $9.5M $57.8M Completed Startup
1. Early Stage VC (Series A) 20-Jul-2007 $6.32M $6.32M $18.6M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Adimab Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series E 00,000 00.000000 000.00 0000.00 00 000.00 0.000
Series D 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series C 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series B 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series A2 1,574,133 $0.001000 $3.76 $3.76 1x $3.76 22.67%
Series A1 300,000 $0.001000 $1.33 $1.33 1x $1.33 4.32%
To view this company’s complete Cap Table request access »

Adimab Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Borealis Ventures Venture Capital Minority 000 0000 000000 0
GV Corporate Venture Capital Minority 000 0000 000000 0
Georges Harik Angel (individual) Minority 000 0000 000000 0
Mithril Capital Management Venture Capital Minority 000 0000 000000 0
OrbiMed Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Adimab Executive Team (11)

Name Title Board
Seat
Contact
Info
Kirt Johnson Associate Director of Product Engineering
Kristin Rookey Director, Alliance Management and Business Development
Anthony Cooper Ph.D Research Scientist
Mary Schiavoni Head, Human Resources
Karl Wittrup Ph.D Co-Founder, Office of the CSO, Chairman of the SAB
You’re viewing 5 of 11 executives. Get the full list »

Adimab Board Members (11)

Name Representing Role Since Contact
Info
Ajay Royan Mithril Capital Management Board Member 000 0000
Carl Gordon Ph.D OrbiMed Board Member 000 0000
Errik Anderson Self Co-Founder 000 0000
Karl Wittrup Ph.D Adimab Co-Founder, Office of the CSO, Chairman of the SAB 000 0000
Marc Elia Self Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »